reports
Curetis N.V. in liquidatie informs on publication of audited FY2019 fi...
Curetis N.V. in liquidatie informs on publication of audited FY2019 financial results and annual report Amsterdam, The Netherlands, and Holzgerlingen, Germany, July 01, 2020, 08:30 am CEST - Curetis N.V. in liquidatie (the "Company") today announced the publication of its audited 2019 full year financial results and 2019 Annual Report. Originally scheduled for April 30, 2020, this was delayed due to the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a purely remote and off-site auditing effort required as part of the ...
Curetis N.V. in liquidatie informs on delay of publication of audited ...
Curetis N.V. in liquidatie informs on delay of publication of audited FY2019 financial results and annual report Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 30, 2020, 08:00 am CET - Curetis N.V. in liquidatie (the "Company") today announced that the publication of its audited 2019 full year financial results and 2019 Annual Report originally scheduled for April 30, 2020 will be delayed to a later date expected in May 2020. The delay is caused by the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a pure...
Curetis N.V. in liquidatie to announce liquidation distribution in adv...
Curetis N.V. in liquidatie to announce liquidation distribution in advance and last trading day Amsterdam, the Netherlands, Holzgerlingen, Germany April 20, 2020, 8:00 am CEST - Curetis N.V. in liquidatie (the "Company") announces that the liquidators of the Company have resolved upon a liquidation distribution in advance to the respective shareholders of the Company (the “Shareholders”), in an amount equal to the value of 1,622,568 shares of OpGen Inc., a Delaware corporation, common stock (the “OpGen Shares”), which distribution shall be satisfied in kind by transferring the OpGen Sha...
Curetis and OpGen Close Business Combination
Curetis and OpGen Close Business Combination - Following approval of shareholders, companies sign German transfer agreement - Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH are now wholly owned by OpGen, Inc. - OpGen consideration shares to be distributed to Curetis N.V. shareholders and Curetis N.V. to be dissolved and delisted from Euronext - Three Curetis N.V. Supervisory Board members resign to join newly formed OpGen Inc. board of directors Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 01, 2020, 10:00 pm CET - Curetis N.V. (in liquida...
Curetis N.V. Informs on OpGen’s Fourth Quarter and Full Year 2019 Fi...
Curetis N.V. Informs on OpGen’s Fourth Quarter and Full Year 2019 Financial Results and Business Update Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transactionTransaction close anticipated by early April 2020Combined OpGen and Curetis business generated $6 million in unaudited pro forma combined 2019 revenue (up from $4.5 million in 2018)First shipments of BGI SARS-CoV-2 rapid PCR kits completed by Curetis in Europe. Additional actions planned to address the global COVID-19 pandemic Amsterdam, the Netherlands, Holzgerlingen, ...
Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus ...
Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe - Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours - Test kit to be made available via Curetis’ European sales channels - Synergies with Curetis Unyvero HPN panel for pneumonia testing for bacterial co-infections in Covid-19 patients Holzgerlingen, Germany, March 16, 2020, 08:00 am CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it starts offering a CE-IVD certified real-...
Curetis N.V. Updates on OpGen, Inc. Special Shareholders’ Meeting He...
Curetis N.V. Updates on OpGen, Inc. Special Shareholders’ Meeting Held on March 10, 2020 Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 16:15 pm CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, reports that a Special Meeting of shareholders of OpGen, Inc. (“OpGen”) held today, March 10, 2020, in Washington DC, USA, to approve the business combination of Curetis and OpGen, was adjourned. Because a quorum was not represented at OpGen’s Special Meeting,...
Curetis N.V. Reports Results of the Extraordinary General Meeting Held...
Curetis N.V. Reports Results of the Extraordinary General Meeting Held on March 10, 2020 - Shareholders adopt all proposed resolutions - EGM votes clear way for closing of business combination with OpGen, Inc., subject to OpGen’s stockholders’ approval - Subsequently Curetis N.V. will be dissolved and shares of OpGen common stock are to be distributed to the shareholders of Curetis N.V. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, XX:00 pm CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of ne...
Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key ...
Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key Financials and Provides Business Update Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018More than tripled total contract order volume received year-over-year to about EUR 3.4 million 2019Curetis N.V. shareholders to vote on March 10, 2020 on planned business combination with OpGen, Inc. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, February 20, 2020, 08:00 am CET -- Curetis N.V. (the "Company" and, together ...
Curetis and Quaphaco Enter into Unyvero Distribution Partnership for V...
Curetis and Quaphaco Enter into Unyvero Distribution Partnership for Vietnam Exclusive distribution agreement for initial term of 3 yearsQuaphaco commits to minimum purchase totaling about EUR 1.9 million during initial term Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, February 6, 2020, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has entered into a distribution agreement with Quaphaco for Vietnam. Quaphaco, headquartered in ...
Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer...
Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCRAres Genetics to launch next-generation sequencing testing service for infection control and monitoring of 2019-nCoV evolution using BGI Group reagentsAres Genetics, Curetis Group and BGI Group to collaborate in the distribution of next-generations sequencing and PCR testing kits for 2019-nCoV Vi...
Curetis to Hold Extraordinary General Meeting on March 10, 2020
Curetis to Hold Extraordinary General Meeting on March 10, 2020 Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 27, 2020, 08:00 am CET / 02:00 am EDT - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, today published the invitation to its Extraordinary General Meeting (EGM). The invitation follows the notice of effectiveness of the OpGen, Inc. S-4 filing received from the SEC on January 23, 2020. Curetis N.V. will hold the EGM on Tuesday, March 10, 2020, at Steigenber...
Curetis To Attend Key Conferences in the First Half of 2020
Curetis To Attend Key Conferences in the First Half of 2020 Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 23, 2020, 10:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the first half of 2020. February 2020First Coast Infectious Disease/Clinical Microbiology Symposium 27th Annual Meeting January 31 – February 1, 2020 – Ponte Vedra Beach, FL (Curetis USA Inc.)March 20204th AMR Conf...
Curetis N.V.: 1 director sold
A director at Curetis N.V. sold 31,236 shares at 0.700EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Curetis Launches Unyvero LRT Panel for BAL Specimens in the U.S.
Curetis Launches Unyvero LRT Panel for BAL Specimens in the U.S. Panel also includes atypical pathogens such as Pneumocystis jiroveciiLRT BAL Panel expected to substantially increase total addressable market for Unyvero System in the U.S. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 14, 2020, 08:00 am CET -- Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced the U.S. launch of its Unyvero LRT BAL Lower Respiratory Tract Application Cartridge for us...
Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Spec...
Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jiroveciiClearance expected to substantially increase total addressable market for Unyvero System in the U.S.Commercial launch in the U.S. expected for Q1-2020 Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, December 20, 2019, 23:30 CET -- Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Co...
Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS...
Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS Activate Programs Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupaNVIDIA Inception program accelerates start-ups that revolutionize industries with advancements in AI Vienna, Austria, and Holzgerlingen, Germany, December 10, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ar...
Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize
Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize Prize awarded by the Vienna Economic Chamber to the most innovative companies in Vienna Ares Genetics´ awarded in the category Life Sciences for its AI-powered Universal Pathogenome Assay - ARESupa Vienna, Austria, and Holzgerlingen, Germany, November 25, 2019, 10:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics was awarded the 2019 MERCUR Innovation Prize by t...
Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Uny...
Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens All formal FDA requests for additional information answeredInteractive review ongoing as review nears completion Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 25, 2019, 08:00 am CET -- Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company has filed its formal response to the FDA’s AI (Additional Information request letter regarding the Comp...
Curetis Publishes Third Quarter and 9-Month Business and Financial Upd...
Curetis Publishes Third Quarter and 9-Month Business and Financial Update - Signed IVD partnership for Ares Genetics - Progressed implementation of the Curetis - OpGen business combination with S4 filing - More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019 - Revenue growth of approximately 16% - Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 25, 2019, 07:00 am CET -- Curetis N.V. (the "Company" and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.